Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Trading Update

19 Jan 2010 07:00

RNS Number : 7435F
Cello Group plc
19 January 2010
 



19 January 2010

  

Cello Group plc

Pre-Close trading update - year ended 31 December 2009

Cello Group plc (AIM: CLL, 'the Group'),  the leading independent market research and consulting group, today publishes the following pre-close trading update for the year ended 31 December 2009 Since the announcement of the Group's interim results published in early September, there has been a marked pick up in its market research activity from a wide range of domestic and international clients, in addition to continued strength in the core pharmaceutical operation. However, this has been offset by a challenging period for aspects of the Tangible division of the Group, most notably in financial services and certain charity related work where the traditional seasonal pick up in client activity was not as robust as anticipated. The Tangible operations based in Scotland have had a strong year. Total Group revenue is expected to be in the region of £60.0m.

As highlighted in the interim results, the Group's cost reduction programme continued in the second halfThe total cost base in 2009 is expected to be between £4.0m and £4.5m lower than 2008 as a result of reduced headcount and property consolidation, which will give rise to an exceptional cost of around £1.9m.

As a result, the Board anticipates that the Group's headline profit before tax will be approximately £5.0m.The Group's strong cash conversion continued in the second half of 2009, as a result of which the Board expects to report year end net debt of between £11.5m and £12.0m, down from £14.8m on 30 June 2009.Whilst the Board remains realistically cautious about the current outlook and it is too early to give detailed guidance for 2010, the Group is seeing refreshed levels of spend across major research clients, with pharmaceutical and health related research showing particular strengthThe pipeline of research work is significantly stronger than at the same time last year. Therefore, following the substantial reduction in low margin and non-profitable activities, the Group is in a strong position to push for organic growth in 2010. The Group expects to announce its preliminary results for the year ended 31 December 2009 on Wednesday 17 March 2010. 

 

Enquiries:

 

Cello Group 

 020 7812 8460

Mark ScottChief Executive

Mark Bentley, Finance Director

 

Altium 

 020 7484 4040

Ben Thorne

Paul Chamberlain

 

College Hill

 020 7457 2020

Adrian Duffield/Rozi Morris

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXFPFELEEFF
Date   Source Headline
11th Jan 20064:35 pmRNSNotifiable Interest
11th Jan 20067:00 amRNSPre Close Trading Statement
3rd Jan 20063:44 pmRNSHolding(s) in Company
19th Dec 20057:17 amRNSAcquisition
16th Dec 20051:57 pmRNSAdditional Listing
25th Nov 200512:53 pmRNSAcquisition
20th Oct 20058:00 amRNSInvestor Presentation
14th Oct 20058:00 amRNSChange of Adviser
3rd Oct 20057:00 amRNSOMP Services
27th Sep 20057:02 amRNSInterim Results
2nd Sep 200511:41 amRNSNotice of Results
1st Aug 20057:00 amRNSAcquisition
18th Jul 20057:00 amRNSAcquisition
14th Jul 20059:14 amRNSHolding(s) in Company
11th Jul 20057:00 amRNSPre Close Trading Statement
4th Jul 20055:44 pmRNSHolding(s) in Company
1st Jul 20057:00 amRNSAcquisition
7th Jun 20052:46 pmRNSDirector Share Option Award
6th Jun 20054:43 pmRNSAcquisition Agreement
23rd May 200512:30 pmRNSAGM Statement
4th May 20058:41 amRNSBoard Appointment
25th Apr 20057:00 amRNSBoard Appointment
14th Mar 20057:01 amRNSFinal Results
10th Mar 20054:18 pmRNSHolding(s) in Company
1st Feb 200512:00 pmRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.